Yang Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yang Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chen Zhu
Department of Orthopedics, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2 shared publications - Jing Zhou
Department of Urology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2 shared publications - Liming Xiong
Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
2 shared publications - Wei Huang
Department of Orthopedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine University of Science and Technology of China Hefei China
2 shared publications - Wei Zhou
Department of Orthopaedics, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2 shared publications - Xuan Nie
Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
2 shared publications
Latest Publications
- Open Access
- 20 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Author Correction: Peptide-based inflammation-responsive implant coating sequentially regulates bone regeneration to enhance interfacial osseointegration
- 20 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessAuthor Correction: Peptide-based inflammation-responsive implant coating sequentially regulates bone regeneration to enhance interfacial osseointegration
- Top Cited PapersOpen Access
- 6 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Peptide-based inflammation-responsive implant coating sequentially regulates bone regeneration to enhance interfacial osseointegration
Aseptic loosening is the primary cause of bone prosthesis failure, commonly attributed to inadequate osseointegration due to coatings misaligned with bone regeneration. Here, we modify the titanium surface with a mussel-inspired peptide to form a 3,4-dihydroxyphenylalanine (DOPA)-rich coating, then graft N3-K15-PVGLIG-K23 (P1) and N3-Y5-PVGLIG-K23 (P2), which are composed of anti-inflammatory (K23), angiogenic (K15), osteogenic (Y5), and inflammation-responsive (PVGLIG) sequences, onto the surface via click chemistry, forming the DOPA-P1@P2 coating. DOPA-P1@P2 promotes bone regeneration through sequential regulation. In the initial stage, the outermost K23 induces M2 macrophage polarization, establishing a pro-regenerative immune microenvironment. Subsequently, K15 and Y5, exposed by the release of K23, enhance angiogenesis and osteogenesis. In the final stage, DOPA-P1@P2 outperforms the TiO₂ control, showing a 161% increase in maximal push-out force, a 207% increase in bone volume fraction, and a 1409% increase in bone-to-implant contact. These findings show that DOPA-P1@P2 efficiently enhances interfacial osseointegration by sequentially regulating bone regeneration, providing viable insights into coating design.
- 6 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-19
Top Cited PapersOpen AccessPeptide-based inflammation-responsive implant coating sequentially regulates bone regeneration to enhance interfacial osseointegration
Aseptic loosening is the primary cause of bone prosthesis failure, commonly attributed to inadequate osseointegration due to coatings misaligned with bone regeneration. Here, we modify the titanium surface with a mussel-inspired peptide to form a 3,4-dihydroxyphenylalanine (DOPA)-rich coating, then graft N3-K15-PVGLIG-K23 (P1) and N3-Y5-PVGLIG-K23 (P2), which are composed of anti-inflammatory (K23), angiogenic (K15), osteogenic (Y5), and inflammation-responsive (PVGLIG) sequences, onto the surface via click chemistry, forming the DOPA-P1@P2 coating. DOPA-P1@P2 promotes bone regeneration through sequential regulation. In the initial stage, the outermost K23 induces M2 macrophage polarization, establishing a pro-regenerative immune microenvironment. Subsequently, K15 and Y5, exposed by the release of K23, enhance angiogenesis and osteogenesis. In the final stage, DOPA-P1@P2 outperforms the TiO₂ control, showing a 161% increase in maximal push-out force, a 207% increase in bone volume fraction, and a 1409% increase in bone-to-implant contact. These findings show that DOPA-P1@P2 efficiently enhances interfacial osseointegration by sequentially regulating bone regeneration, providing viable insights into coating design.